Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard
mi
from
Fort Wayne, IN
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
BCCA-Vancouver Cancer Centre
mi
from
Vancouver,
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
BCCA-Vancouver Cancer Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Scottsdale Healthcare Research Institute
mi
from
Scottsdale, AZ
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Scottsdale Healthcare Research Institute
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Westchase Oncology Center
mi
from
Houston, TX
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Westchase Oncology Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Morbidity After Diagnosis and Treatment of Breast Cancer Patients
A Prospective (Cohort) Study to Identify Factors Affecting Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center (BCC)
Status: Enrolling
Updated:  12/31/1969
National Naval Medical Center
mi
from
Bethesda, MD
Morbidity After Diagnosis and Treatment of Breast Cancer Patients
A Prospective (Cohort) Study to Identify Factors Affecting Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center (BCC)
Status: Enrolling
Updated: 12/31/1969
National Naval Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study
Immunologic Studies of Tumors of the Pancreas
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study
Immunologic Studies of Tumors of the Pancreas
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center
mi
from
Modesto, CA
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center
mi
from
Modesto, CA
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Naval Medical Center - San Diego
mi
from
San Diego, CA
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
North Colorado Medical Center
mi
from
Greeley, CO
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Elmhurst Memorial Hospital
mi
from
Elmhurst, IL
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Elmhurst Memorial Hospital
mi
from
Elmhurst, IL
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Community Hospital
mi
from
Munster, IN
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Community Hospital
mi
from
Munster, IN
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Ochsner Health Center - Covington
mi
from
Covington, LA
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Ochsner Health Center - Covington
mi
from
Covington, LA
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Harold Alfond Center for Cancer Care
mi
from
Augusta, ME
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Harold Alfond Center for Cancer Care
mi
from
Augusta, ME
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Sturdy Memorial Hospital
mi
from
Attleboro, MA
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Sturdy Memorial Hospital
mi
from
Attleboro, MA
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Berkshire Hematology Oncology, PC
mi
from
Pittsfield, MA
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Berkshire Hematology Oncology, PC
mi
from
Pittsfield, MA
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Mercy Memorial Hospital
mi
from
Monroe, MI
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Mercy Memorial Hospital
mi
from
Monroe, MI
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Jackson Oncology Associates
mi
from
Jackson, MS
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Great Falls Clinic
mi
from
Great Falls, MT
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Great Falls Clinic
mi
from
Great Falls, MT
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Northern Montana Hospital
mi
from
Havre, MT
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Northern Montana Hospital
mi
from
Havre, MT
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Foundation Medical Partners
mi
from
Nashua, NH
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Foundation Medical Partners
mi
from
Nashua, NH
Click here to add this to my saved trials
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Hormone Therapy With or Without Combination Chemotherapy in Treating Node-Negative Breast Cancer (The TAILORx Trial)
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials